Patient-Reported Outcomes (Pros) From The Phase Iii Imbrave150 Trial Of Atezolizumab (Atezo) Plus Bevacizumab (Bev) Vs Sorafenib (Sor) As First-Line Treatment (Tx) For Patients (Pts) With Unresectable Hepatocellular Carcinoma (Hcc)
JOURNAL OF CLINICAL ONCOLOGY（2020）
摘要
476Background: Atezo + bev in pts with unresectable HCC who had not received prior systemic therapy has shown statistically significant and clinically meaningful improvement in OS and PFS per indep...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要